Latest From Mallinckrodt PLC
Zydus says its Moraiya plant should be ready for re-inspection at the end of June 2020, following a recent FDA warning letter. Meanwhile, as returns from levorphanol fall on the back of increased competition, the firm has written down investment by $37.5m causing Q2 profits to slump 74%. Post successful Phase II trials in the US for NASH and NAFLD indications, its hopes are now pinned on saroglitazar magnesium.
Novartis and Roche will present alongside up-and-coming biotechs and microcaps..
As returns from levorphanol fall on the back of increased competition, Zydus Cadila writes down investment by $37.5m causing Q2 profits to slump 74%. Post successful Phase II trials in the US for NASH and NAFLD indications, its hopes are now pinned on saroglitazar magnesium.
Teva and three distributors settle with two plaintiffs; PBMs are defendants in next case as Teva also reaches an agreement in principal with four attorneys general for global settlement framework.
- Medical Devices
- Generic Drugs
- Specialty Pharmaceuticals
- Therapeutic Areas
- Immune Disorders
- Metabolic Disorders
- Neurology, Nervous System
- Renal System
- Respiratory, Pulmonary
- Mallinckrodt LLC
- Mallinckrodt Inc.
- Mallinckrodt Group, Inc.
- Mallinckrodt Pharmaceuticals
- Western Europe
- Parent & Subsidiaries
- Mallinckrodt PLC
- Senior Management
Mark Trudeau, Pres. & CEO
George Kegler, EVP and CFO, Interim
Steven Romano, MD, EVP, CSO
Matthew Harbaugh, President, Specialty Generics
Hugh O'Neill, EVP and Chief Commercial Officer
Dagmar Rosa-Bjorkeson, Chief Strategy and Corp Dev Officer
Frank Scholz, PhD, EVO and Chief Operations/Digital Innovation
- Contact Info
Phone: 17 8463 6700
3 Lotus Park
Staines-Upon-Thames, MO TW18 3AG
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.